Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

BTIG raised the firm’s price target on Protagonist Therapeutics (PTGX) to $73 from $67 and keeps a Buy rating on the shares. Positive VERIFY ...

Despite there being an overall trend toward better representation, Dames 4 Games hopes for a world where Black/female-led ...

The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

"Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in ...